26with manufacturer's recommendations [11]. All together there were 232 cases of 3 nosologic emergency conditions proven as bound with hypoxic, energy deficit and vegetative homeostasis disregulative statuses [3,4,7,10,[13][14][15]. These emergency conditions were: acute coronary syndrome without Q but linked with arterial hypertension (ACS+AH), ischemic stroke (IS), liver resections (LR). Certified medical specialists (therapists, cardiologists, neurologists, surgeons, emergency specialists) evaluated clinical status dynamics for all the participating patients and fixed data in clinical documents. Patient data included the following informational clusters: 1). Symptoms, syndromes before and after the treatment according to clinical, laboratory, instrumental tests; 2). Drug administration (dosage for single intake and all the curse signature, the intake methods as pre os, intravenous etc.). The intake time was also under estimation, as well as the signs of coming effects/ ineffectiveness. Actual costs of medication included not only pharmacological agents, but also syringes, intravenous infusion systems etc.; 3). Marks about complications, adverse effects during the supervision period; 4). Complicated accounts of economic costs incl. medication (see p. 2), expenses of complicated medical services with hospital stay, diagnostic applications, additional complication treatment, medical specialists' fee. Web resource "Kirov pharmacy costs" allowed to appreciate the drugs' prices [19]. Economic departments of research-involved hospitals helped to assure precisely all the other expenses mentioned above. Transitory (surrogate) pathology specific markers of effectiveness served as quantitative and qualitative frequency parameters of reamberin effects. Effectiveness calculation were rates of positive clinical outcomes (% of patients with main symptoms disappear, with somatic status improvement, % of complications' number decrease during fixed time cut) in BT and BT + R groups. Statistical tools with χ 2 criteria and p<0,05 were used. The unified indicators of clinical efficiency were IAA (increase of absolute advantage), IRA (increase of relative advantage), NNT (number needed to treat -number of patients to treat traditionally during certain time for a favorable outcome comparable to a new way), OR (odds ratio -relation of improved outcome chances) and their 95% confidential intervals (95% of CI). The mathematic tool was meta-analysis calculator WinPepi published in the Internet network [1,12,20]. Sensitivity analysis [18] implied intra-and intergroup heterogeneity of indicative responses (χ 2 , p< 0,1), «expense/ efficiency» (CER) coefficient's variability range dependent of minimal and maximal entire treatment drug dosage costs. As the work's aim was to integrate data of the same treatment efficiency (with/ without reamberin additionally) in patients with emergencies like myocardium damage, acute failure of cerebral blood supply or surgical aggression, also to form the conclusion about clinical and clinic-economic (pha...

The authors carried out a systematic review and subsequent meta-analysis of randomized clinical trials evaluating the efficacy of the immunomodulator agent cycloferon as tablets in adults and children with viral respiratory diseases. A total estimate of its clinical efficacy was obtained in terms of compared heterogeneous groups and response variables. The data published in 16 articles were used to calculate the formal parameters of the clinical efficacy of cycloferon (increased absolute and relative benefits, odds ratio (OR); the number of patients needed to be additionally treated with cycloferon to achieve a favorable outcome or to prevent a poor outcome in one patient, etc.). High heterogeneity hampered the unequivocal interpretation of results; however, combining the compared homogeneous groups in the meta-analysis (with adjustments for fixed and random effects) increased the statistical power of the investigation. In children aged 6 to 18 years, the OR for the positive effect of the drug (no new cases after its preventive administration) was 5.3 (95% confidence interval (CI), 4.8-5.9), heterogeneity test, χ = 249.5; p=0.000...; I = 94.8% (95% CI, 92.7-96.3%). This suggested the heterogeneity of clinical trial data and extrapolated this estimate to medical practice. The use of cycloferon in adults to treat acute respiratory viral infection enhanced their chances of enduring the disease in a mild form and avoiding serious complications: the OR for positive outcomes was 9.7 (95% CI, 7.0-13.0), while the effect was more homogeneous than in children (heterogeneity test, χ = 7.4; p=0.061...; I = 59.4% (95% CI, 0-86.5). Thus, the use of cycloferon to treat and prevent acute viral respiratory infections showed a more than 5-fold increase in the probability of avoiding the disease or enduring the latter in a mild form.

Группа острых инфекционных поражений дыхательной системы, вызываемых представителями семейства Coronaviridae, изучается специалистами многих стран уже довольно давно [1,2]. Полученные результаты остаются приоритетным источником данных о возможностях эпиде-миологического и медикаментозного контроля пандемии COVID-19, окончательная победа над которой до сих пор не очевидна.Индукторы интерферонов на основе акридин-уксусной кислоты (АУК, часто встречается синонимическое название -карбоксиметил-акриданон, КМА) также имеют длительную историю разработок, испытаний и модернизаций [3][4][5]. В